96 results on '"Bokemeyer, C."'
Search Results
2. Diagnosis, treatment, and use of intravenous iron for chemotherapy-induced anemia in Europe.
3. Relationship of T lymphocytes, T regulatory cells, and B lymphocytes to clinical outcome in prostate cancer.
4. Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies.
5. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab.
6. The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase ll/lll study.
7. The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer.
8. The role of the KRAS G13D mutation in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy plus cetuximab.
9. Outcome according to metastatic site in patients with KRAS wild-type tumors: Analysis from the CRYSTAL and OPUS studies.
10. Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: Lessons from the OPUS trial.
11. Relationship of YKL-40 protein expression in pulmonary adenocarcinoma and prognosis.
12. Analysis of four human PlGF isoforms and of VEGFR-1 in esophageal carcinoma.
13. MicroRNA expression in paternal and cisplatin-resistant germ cell tumor cell lines.
14. Expression of the cancer-testis antigen FMR1NB on the surface of malignant cells.
15. Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: A CUOG/GTCSG cooperative phase II study.
16. An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) < 9 g/dl vs 9 to < 10 g/dl versus ≥ 10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA).
17. Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos).
18. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.
19. Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer.
20. Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy.
21. Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin ± paclitaxel.
22. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
23. High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ cell tumors
24. Analysis of expression of TGF-β1 receptor (ALK-1) in normal and tumor tissues by tissue microarrays
25. Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites
26. Use of the Comprehensive Geriatric Assessment (CGA) in elderly patients (pts) with solid tumors to predict mortality
27. Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report
28. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN
29. Patterns of relapse after primary or salvage high-dose chemotherapy in patients with advanced nonseminomatous germ cell tumors
30. Elevated pretreatment serum concentration of YKL-40—An independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer
31. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301)
32. Chemokine CXCL13 is overexpressed in the tumor tissue and in the peripheral blood of breast cancer patients
33. Effects of aerobic exercise training on physical performance during myeloablative therapy
34. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
35. BCR/ABL status of blood outgrowth endothelial cells from CML patients
36. Results from the pilot phase of the IN-GHO registry for elderly cancer patients
37. A randomised phase II study of gemcitabine versus mitomycin C versus gemcitabine/mitomycin C in patients with advanced pancreatic cancer
38. Global proteome analysis of germ cell tumor (GCT) cell lines under treatment with cisplatin (CDDP)
39. Analysis of 94 patients with advanced biliary tract cancer
40. The tyrosine kinase src plays a crucial role in leukemic cell proliferation in AML
41. Combination chemotherapy with gemcitabine, oxaliplatin and paclitaxel in patients with cisplatin-refractory or relapsed germ cell tumors (gct)
42. Booster vaccination of non-small cell lung cancer (NSCLC) patients with MAGEA3 protein and AS02B adjuvant
43. Leptomeningeal metastases: Results of different therapeutic approaches
44. Comparison of combination treatment with endostatin, soluble neuropilin-1 and thrombospondin-2 to single inhibitors in antiangiogenic therapy of renal cell carcinoma
45. A pilot study of weekly docetaxel and daily trofosfamide as metronomic second-line chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
46. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study
47. Outcome in 41 patients with late relapse germ cell tumors (GCT) treated with high-dose chemotherapy (HDCT)
48. Phase I trial of SU014813 in patients (pts) with advanced solid malignancies
49. RESPOND - Raising awareness of anemia in oncology centers through computer algorithm driven guidelines: Assessment of intraclass correlation metrics for the accuracy of algorithmic definitions
50. Detection of circulating lymphendothelial cells in patients with solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.